A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Conditions:   Advanced Solid Tumor;   Unresectable Solid Tumor;   Melanoma;   Renal Cell Carcinoma;   Sarcoma;   Triple Negative Breast Cancer;   Pancreatic Ductal Adenocarcinoma;   Non-Small Cell Lung Cancer Squamous;   Non-Small Cell Lung Cancer Non-squamous;   Colorectal Cancer;   Gastric Cancer;   Biliary Tract Cancer;   Gallbladder Cancer;   Cholangiocarcinoma;   Uterine Cancer;   Ovarian Cancer;   Cervical Cancer;   Basal Cell Carcinoma;   Bladder Cancer;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   Cutaneous Squamous Cell Carcinoma
Interventions:   Drug: MDNA11 Monotherapy;   Drug: MDNA11 in combination with checkpoint inhibitor
Sponsor:   Medicenna Therapeutics, Inc.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 18, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine